Soru

Zorluk: Çok zorInterpreting Laboratory Results

A 48-year-old man presents to the clinic with a 7-month history of progressive, deep bone pain in his ribs, hips, and lower extremities, along with significant proximal muscle weakness. He reports difficulty climbing stairs and rising from a seated position. He has no significant past medical history, takes no medications, and consumes a well-balanced diet. He works as a construction manager and spends a significant amount of time outdoors.

Vital signs are within normal limits. Physical examination reveals a waddling gait and diffuse bony tenderness upon palpation of the rib cage and anterior pelvis. Neurologic examination shows 4/5 motor strength in the proximal muscles of the bilateral lower extremities with normal deep tendon reflexes.

Laboratory results are as follows:

Serum ChemistryValueReference Range
Sodium140 mEq/L136-145 mEq/L
Potassium4.1 mEq/L3.5-5.0 mEq/L
Chloride104 mEq/L98-106 mEq/L
Bicarbonate24 mEq/L22-28 mEq/L
BUN14 mg/dL8-20 mg/dL
Creatinine0.9 mg/dL0.7-1.3 mg/dL
Calcium8.7 mg/dL8.4-10.2 mg/dL
Phosphorus1.4 mg/dL2.5-4.5 mg/dL
Alkaline phosphatase380 U/L40-120 U/L
Additional StudiesValueReference Range
Parathyroid hormone (PTH)45 pg/mL10-65 pg/mL
25-hydroxyvitamin D36 ng/mL20-50 ng/mL
1,25-dihydroxyvitamin D11 pg/mL18-72 pg/mL
Urine FE of phosphorus26%< 5% (in hypophosphatemia)

Urinalysis is negative for protein, glucose, and blood, with a pH of 6.0.

Which of the following best describes the primary pathophysiologic mechanism underlying this patient's clinical and laboratory findings?

  1. A
    Autonomous hypersecretion of parathyroid hormone
  2. Ectopic secretion of fibroblast growth factor 23Cevap
  3. C
    Generalized dysfunction of the renal proximal tubule
  4. D
    Inactivating mutation of the PHEX gene
  5. E
    Inadequate dietary intake and limited cutaneous synthesis of cholecalciferol

Cevap

The correct underlying mechanism is the ectopic secretion of fibroblast growth factor 23, which is characteristic of tumor-induced osteomalacia.
The correct diagnosis is the ectopic secretion of fibroblast growth factor 23 (FGF23). This patient presents with acquired adult-onset osteomalacia (manifesting as bone pain, muscle weakness, and elevated alkaline phosphatase) driven by severe hypophosphatemia. The inappropriately high fractional excretion of phosphorus (26%) in the setting of low serum phosphorus indicates renal phosphate wasting. Furthermore, his 1,25-dihydroxyvitamin D is inappropriately low. Under normal physiologic conditions, hypophosphatemia powerfully stimulates renal 1-alpha-hydroxylase to increase 1,25-dihydroxyvitamin D production. The paradoxical suppression of this enzyme alongside active renal phosphate wasting is the definitive biochemical hallmark of excess FGF23. In a previously healthy adult without a childhood history of rickets or bowing deformities, this pattern is highly specific for tumor-induced osteomalacia (TIO). TIO is a paraneoplastic syndrome caused by small, benign phosphaturic mesenchymal tumors that ectopically secrete FGF23.

Adım Adım Çözüm

1
Identify the primary metabolic abnormalities from the provided laboratory panels.
The patient has severe isolated hypophosphatemia and elevated alkaline phosphatase (indicating osteomalacia), with normal serum calcium and PTH.
Establishing the core derangements is the first step in formulating a differential diagnosis for metabolic bone disease.
2
Determine the etiology of the hypophosphatemia using the urine studies.
The fractional excretion of phosphorus is 26%, which is inappropriately high given the severe hypophosphatemia (expected to be <5%).
This localizes the defect to isolated renal phosphate wasting, ruling out decreased intestinal absorption or internal cellular redistribution.
3
Analyze the vitamin D axis to narrow the cause of the renal phosphate wasting.
25-hydroxyvitamin D is normal, but 1,25-dihydroxyvitamin D is paradoxically suppressed despite the strong stimulatory effect hypophosphatemia normally exerts on 1-alpha-hydroxylase.
The combination of renal phosphate wasting and suppressed 1-alpha-hydroxylase activity is the specific biochemical signature of excess Fibroblast Growth Factor 23 (FGF23).
4
Synthesize the laboratory profile with the patient's demographics to identify the underlying disease.
Acquired FGF23 excess in a previously healthy adult is highly specific for ectopic FGF23 secretion from a mesenchymal tumor.
This perfectly explains the clinical presentation of tumor-induced osteomalacia (TIO), distinguishing it from inherited childhood disorders with the same lab profile (like X-linked hypophosphatemia).

Anahtar Kavram

Interpretation of renal phosphate wasting syndromes and the pathophysiologic effects of Fibroblast Growth Factor 23 (FGF23) in tumor-induced osteomalacia.
Tahmini Süre:2m 30s
Bu soruyu puanla